Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart, Anlotinib, and Etoposide in First-Line Treatment of SCLC
NCT07728955Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Aug 2026
- Primary completion
- Dec 2027
01
Overview
A Phase 3 trial of benmelstobart in small cell lung cancer (SCLC), sponsored by Sun Yat-sen Memorial Hospital. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
benmelstobart
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07728955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07728955.